Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DJ8TN2
|
|||
| Drug Name |
HL-085
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 1/2 | [1] | |
| Company |
Kechow Pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | ERK activator kinase (MEK) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03973151) Study of HL-085 in NRAS Mutant Advanced Melanoma. U.S. National Institutes of Health. | |||
| REF 2 | Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.